Medicine, Hematology Oncology Division

Grants

Grants per year 1995 2006 2007 2008 2009 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2034

• 1 Not started
• 409 Active
• 1283 Finished

Grants per year

Search results

• Biochemical and Genetic Studies of Latent Membrane Pro 2

  Longnecker, R. M. & Ikeda, M.

  National Cancer Institute

  7/1/03 → 4/30/08

  Project: Research project

  • Epstein Barr Virus 100%
  • epstein-barr virus 100%
  • proteins 60%
  • B Lymphocyte 50%
  • lymphocytes 50%

• Division of Hematology/Oncology Fellowship Training Program (Request ID# 10008905)

  Gradishar, W. J.

  Ortho Biotech Inc.

  7/1/03 → 6/30/05

  Project: Research project

• Prot# NU 02H8 (PCYC-0213): A Phase I/II Trial of Redox Regulation in Patients with Relapsed or Refractory CD20 Positive Non-Hodgkin's Lymphoma (NHL): Combining 90Yttrium-Zevalin & Redox-Modulating Agent, Motexafin Gadolinium (MGd)

  Gordon, L. I., Kuzel, T. M., Singhal, S., Spies, S. M., Tallman, M. S., Williams, S. F. & Winter, J. N.

  Pharmacyclics, Inc.

  7/23/03 → 9/1/11

  Project: Research project

• Prot# C-300-01: Phase II Study of AG-858 Plus Gleevec? In Patients with Chronic Myelogenous Leukemia (CML) In Chronic Phase Who Are Cytogenetically Positive After Treatment with Gleevec?

  Tallman, M. S.

  Agenus Inc.

  8/28/03 → 1/1/11

  Project: Research project

• Prot# NU E03I2: An Oral Solution for Chemotherapy Induced Diarrhea (CID) (ENHRI Prot# EH01-132)

  Benson III, A. B.

  NorthShore University HealthSystem Research Institute, Pfizer Inc.

  8/29/03 → 12/31/05

  Project: Research project

• Regulation of MMP's by E-Cadherin in Oral Cancer

  Munshi, H. G.

  American Cancer Society

  9/1/03 → 8/31/04

  Project: Research project

• ICSBP Function During Myeloid Differentiation

  Eklund, E. A.

  National Cancer Institute

  9/1/03 → 8/31/08

  Project: Research project

  • Interferon Consensus Sequence Binding Protein 100%
  • IRF8 100%
  • Myeloid Differentiation 38%
  • Myeloid 33%
  • Protein Phosphorylation 27%

• MAP Kinase Pathways as Therapeutic Targets in Chronic Myelogenous Leukemia

  Platanias, L. C.

  U.S. Army Medical Research and Materiel Command

  9/1/03 → 12/30/06

  Project: Research project

• Prot# CC-5013-MM-014: A Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Single Agent CC-5013 in Subjects with Relapsed and Refractory Multiple Myeloma

  Singhal, S.

  Celgene Corporation

  9/2/03 → 12/30/05

  Project: Research project

• Depressive State and Cell Resistance to Stress in Cancer

  Gradishar, W. J.

  National Cancer Institute

  9/5/03 → 2/28/07

  Project: Research project

  • Depression 100%
  • cancer 75%
  • Cells 62%
  • Malignant Neoplasm 62%
  • therapy 50%

• Prot# NU 02H8 (PCYC-0213): A Phase I/II Trial of Redox Regulation in Patients with Relapsed or Refractory CD20 Positive Non-Hodgkin's Lymphoma (NHL) Combining 90-Yttrium-Zevalin® and the Redox-Modulating Agent, Motexafin Gadolinium (MGd) (Prot# 106-P115)

  Gordon, L. I., Kuzel, T. M., Singhal, S., Spies, S. M., Tallman, M. S., Williams, S. F. & Winter, J. N.

  Biogen Inc.

  9/5/03 → 1/1/11

  Project: Research project

• CAREER: Cadherin-Mediated Regulation of MMPs in Oral Cancer

  Munshi, H. G.

  National Cancer Institute

  9/11/03 → 8/31/08

  Project: Research project

• Research for Adverse Drug-Events and Reports (RADAR): Supplement 3

  Belknap, S. M., Benson III, A. B., Gordon, L. I., Kuzel, T. M., Tallman, M. S., Weitzman, S. A. & West, D. P.

  National Cancer Institute

  9/15/03 → 8/31/07

  Project: Research project

  • drugs 100%
  • Adverse Drug Reaction 86%
  • Drug 26%
  • information 13%
  • Malignant Neoplasm 10%

• Research for Adverse Drug-Events and Reports (RADAR)

  Benson III, A. B., Gradishar, W. J., Kwaan, H. C. & Tallman, M. S.

  National Cancer Institute

  9/15/03 → 8/31/07

  Project: Research project

  • drugs 100%
  • Adverse Drug Reaction 86%
  • Drug 26%
  • information 13%
  • Malignant Neoplasm 10%

• Improving Functioning in Peripheral Arterial Disease

  McDermott, M. M., Dyer, A. R., Green, D., Greenland, P., Liu, K., Lloyd-Jones, D. M., Pearce, W. H., Schneider, J. R. & Van Horn, L.

  National Heart, Lung, and Blood Institute

  9/22/03 → 7/31/10

  Project: Research project

• Prot# EFC3491: Van Gogh-DVT Trial, A Mltctr, Int'l, Rndmzd, Opn-Lbl, Assessor-Blind, Non-Inferiority Study Comparing Effcy & Sfty of 1x-Wkly Subcutaneous SanOrg34006 w/ Comb'n of (LMW)Heparin & Vitamin K Antagonist (VKA) in Trtm't of Acute Symptomatic Dee

  Green, D.

  Sanofi-Synthelabo Inc.

  10/17/03 → 1/1/11

  Project: Research project

• Facilitating Decision Making in Advanced Cancer Patients

  Benson III, A. B.

  Fox Chase Cancer Center, National Cancer Institute

  11/1/03 → 7/31/06

  Project: Research project

• Prot# Hx-CD4-008: An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, A Fully Human Monoclonal Anti-CD4 Antibody, in Patients with Advanced Stage (IIA-IVB) Cutaneous T-Cell Lymphoma

  Kuzel, T. M. & Zakarija, A.

  Genmab A/S

  11/13/03 → 3/30/04

  Project: Research project

• Prot# F2: Prospective Collection of Data of Possible Prognostic Relevance in Patients with Follicular Lymphoma (NU Prot# NU IFLP-F2)

  Gordon, L. I.

  Angela Serra Association for Cancer Research

  12/1/03 → 1/1/11

  Project: Research project

• Preclinical Trial of Rituxan-Generated, Pre-Apoptotic Redox Regulation in CLL, Lymphoma & Myeloma Cell Lines

  Gordon, L. I.

  Biogen Inc.

  12/18/03 → 12/31/11

  Project: Research project

• Prot# TPU-S1101: A Phase I/II, Open-Label, Nonrandomized, Dose-Finding, Safety, Tolerance, Pharmacokinetic and Efficacy Study of Orally Administered S-1 in Combination with Cisplatin in Patients with Advanced Gastric Cancer

  Benson III, A. B., Flaum, L. E., Frankfurt, O. & Zakarija, A.

  Taiho Pharma U.S.A., Inc.

  1/1/04 → 11/1/11

  Project: Research project

• Prot# EDOAGL-8725-001: A Phase III, Randomized, Open-Label Study of IV Edotecarin vs. Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients w/Glioblastoma Multiforme that has Progressed/Recurred after Alkylator-Based (Neo)Adjuvant Chemotherapy

  Raizer, J. J., Flaum, L. E., Frankfurt, O. & Zakarija, A.

  Pharmacia & Upjohn, Inc.

  2/4/04 → 12/6/05

  Project: Research project

• Prot# OSI2542s: Multicenter Phase II Trial of OSI-774 (Erlotinib, Tarceva?) in Patients with Advanced Bronchioloalveolar Cell Lung Cancer (NU Prot# NU MSK03L1)

  Patel, J. D., Flaum, L. E., Frankfurt, O. & Zakarija, A.

  Genentech, Inc.

  2/5/04 → 12/8/11

  Project: Research project

• Prot# C023: ProMune? (CPG 7909 Injection) With or Without Chemotherapy for the Treatment of Stage III b/c or IV Melanoma: A Randomized, Multi-Center, Open Label, Parallel Group, Active-Controlled, Phase II/III Study

  Kuzel, T. M.

  Quintiles, Inc., Coley Pharmaceutical Group, Inc.

  2/17/04 → 8/22/07

  Project: Research project

• Prot# 9238IL/0048: Rndmzd, Dbl-Bld, Mltctr Study to Compare Effic & Tolrblty of Fulvestrant (FASLODEX?) vs Exemestane (AROMASIN?) in Postmenopausal Women w/ Hormone Receptor Positive Advanced Breast Cancer w/ Disease Progression after Prior Non-Steroidal

  Gradishar, W. J., Flaum, L. E., Frankfurt, O. & Zakarija, A.

  AstraZeneca LP

  2/18/04 → 11/21/11

  Project: Research project